BMRN

Biomarin Pharmaceutical Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 7/10
  • Momentum↑ 5/10
Biomarin Pharmaceutical sales and earnings growth
BMRN Growth
Good
  • Revenue Y/Y↑ 12.39%
  • EPS Y/Y↑ 60.00%
  • FCF Y/Y↑ 152.25%
Biomarin Pharmaceutical gross and profit margin trends
BMRN Profitability
Good
  • Gross margin ↑ 81.30%
  • EPS margin↑ 16.80%
  • ROIC↓ 12.20%
Biomarin Pharmaceutical net debt vs free cash flow
BMRN Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 64.5

Biomarin Pharmaceutical stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗